Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Mar 1;76(3):337-338.
doi: 10.1001/jamapsychiatry.2018.3990.

Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder

Gihyun Yoon  1 , Ismene L Petrakis  1 , John H Krystal  1
Affiliations
Clinical Trial

Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder

Gihyun Yoon et al. JAMA Psychiatry. .

Abstract

This study examines whether naltrexone pretreatment interferes with the antidepressant effects of ketamine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Petrakis reports personal fees from Alkermes outside the submitted work and has a patent to combination of opioid antagonist with ketamine pending. Dr Krystal has been a consultant for AstraZeneca Pharmaceuticals, Biogen, Biomedisyn Corporation, Bionomics, Concert Pharmaceuticals, Heptares Therapeutics, Janssen Research & Development, L.E.K. Consulting, Otsuka America Pharmaceutical, Spring Care Inc, Sunovion Pharmaceuticals, Takeda, and Taisho Pharmaceutical Co; is on the scientific advisory boards of BiOasis Technologies, Biohaven Pharmaceuticals, BlackThorn Therapeutics, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cadent Therapeutics, Lohocla Research Corporation, Pfizer Pharmaceuticals, and Stanley Center for Psychiatric Research at the Broad Institute; has stock in ArRETT Neuroscience, BlackThorn Therapeutics, Biohaven Pharmaceuticals, and Spring Care; has stock options with Biohaven Pharmaceuticals; has the following patents and inventions: Seibyl JP, Krystal JH, Charney DS, Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia, US patent number 5,447,948, September 5, 1995; Coric V, Krystal JH, Sanacora G, Glutamate modulating agents in the treatment of mental disorders, US patent number 8,778,979, July 15, 2014; Coric V, Krystal JH, Sanacora G, Glutamate agents in the treatment of mental disorders, US patent application number 15/695,164, September 5, 2017. Charney D, Krystal JH, Manji H, Matthew S, Zarate C, Intranasal administration of ketamine to treat depression, US patent number 14/197,767, March 5, 2014; Charney DS, Manji HK, Krystal JH, Matthew SJ, Zarate CA, Intranasal administration of ketamine to treat depression, US application or Patent Cooperation Treaty International application number 14/306,382, filed on June 17, 2014; Zarate C, Charney DS, Manji HK, Mathew, Sanjay J, Krystal JH, Methods for treating suicidal ideation, US patent application number 14/197,767 filed on March 5, 2014, by Yale University; Arias A, Petrakis I, Krystal JH, Composition and methods to treat addiction, provisional use patent application number 61/973/961 filed on April 2, 2014, by Yale University; Chekroud A, Gueorguieva R, Krystal JH, Treatment selection for major depressive disorder, June 3, 2016, USPTO docket number Y0087.70116US00, provisional patent submission by Yale University; and Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. USPTO No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University; and has received nonfederal research support from AstraZeneca Pharmaceuticals, which provides the drug saracatinib for research related to US National Institute on Alcohol Abuse and Alcoholism grant Center for Translational Neuroscience of Alcoholism, and from Pfizer Pharmaceuticals, which provides an investigational drug, PF-03463275, for research related to US National Institutes of Health grant Translational Neuroscience Optimization of GlyT1 Inhibitor. All authors (Drs Yoon, Petrakis, and Krystal) are listed as inventors on a patent application by Yale University (application no. PCT/US2017/056922; Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases).

Figures

Figure.
Figure.. Depressive Symptoms From Baseline to Fourth Ketamine Infusion During the Combination of Naltrexone and Ketamine Treatment
The number in parentheses indicates the minutes before or after ketamine infusion; Inf, ketamine infusion; MADRS, Montgomery-Åsberg Depression Rating Scale.
See this image and copyright information in PMC

Comment in

References

    1. Sanacora G, Frye MA, McDonald W, et al. ; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments . A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080 - DOI - PubMed
    1. Williams NR, Heifets BD, Blasey C, et al. . Attenuation of antidepressant effects of ketamine by opioid receptor antagonism [published online August 29, 2018]. Am J Psychiatry. doi:10.1176/appi.ajp.2018.18020138 - DOI - PMC - PubMed
    1. George MS. Is there really nothing new under the sun? is low-dose ketamine a fast-acting antidepressant simply because it is an opioid? [published online August 29, 2018]. Am J Psychiatry. doi:10.1176/appi.ajp.2018.18070800 - DOI - PubMed
    1. Krystal JH, Madonick S, Perry E, et al. . Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology. 2006;31(8):1793-1800. doi:10.1038/sj.npp.1300994 - DOI - PubMed
    1. Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology. 1999;90(1):174-182. doi:10.1097/00000542-199901000-00023 - DOI - PubMed

Publication types